|
|
|
Hair Loss Study Abstract: Study of clinical usefulness of an antiandrogen, TZP-4238, as a drug for treatment of benign prostatic hypertrophy--its influence on sexual function
|
Title
[Study of clinical usefulness of an antiandrogen, TZP-4238, as a drug for treatment of
benign prostatic hypertrophy--its influence on sexual function]
Author
Kumamoto Y; Tsukamoto T; Aoki M; Sato Y; Umehara T; Yoshida O; Arai Y; Kubo T; Aoki H;
Komatsu Y; et al
Address
Department of Urology, Sapporo Medical College.
Source
Hinyokika Kiyo, 40: 8, 1994 Aug, 745-59
Abstract
Using chlormadiNone acetate (CMA) as the control drug, a double-blind study was carried
out to examine not only the effects of 17
alpha-acetoxy-6-chloro-2-oxa-4,6-pregnadiene-3,20-dione (TZP-4238;) on subjective urinary
symptoms but also, especially, that on the sexual function in patients with benign
prostatic hypertrophy (BPH). The clinical efficacy rate in relation to the subjective
urinary symptoms was about the same in the two treatment groups; 45.9% in the TZP-4238
group and 50.0% in the CMA group. However, the incidence of adverse effects on the sexual
function showed a marked difference between the two groups. The TZP-4238 group revealed a
lower suppressive effect on the function than the CMA group (45.1% vs. 71.4%). In relation
to their causation of other adverse effects, there were no differences between the two
drugs. Accordingly, in consideration of the facts that TZP-4238 with less influence on the
sexual function affords a superior quality of life to elderly patients, while achieving
effective treatment by means of a convenient single daily administration, TZP-4238 was
surmised to be a more useful drug than CMA as an antiandrogen for the treatment of BPH.
Language of Publication
Japanese
Unique Identifier
95028864
content2 |
|
